TSLA
Tesla
-- 462.280 AMD
Advanced Micro Devices
-- 126.290 NVDA
NVIDIA
-- 140.220 PLTR
Palantir
-- 82.380 AVGO
Broadcom
-- 239.680 
NEWE
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
VYNE Therapeutics announced positive results from the multiple ascending dose (MAD) portion of its Phase 1a trial for VYN202, a novel BD2-selective BET inhibitor. The study demonstrated a favorable safety and tolerability profilewith no serious adverse events or drug-related issues historically associated with earlier BET inhibitors.
Key findings include: favorable pharmacokinetics supporting once-daily dosing, dose-dependent exposure reaching steady state after 7 doses, and robust pharmacodynamic activity. The drug showed no interaction with methotrexate and demonstrated dose-dependent increases in target engagement biomarker HEXIM-11, with maximal effect at 0.5mg to 1.0 mg QD. VYN202 also inhibited multiple inflammatory biomarkers related to Th17 and Th1/myeloid activity.
Key findings include: favorable pharmacokinetics supporting once-daily dosing, dose-dependent exposure reaching steady state after 7 doses, and robust pharmacodynamic activity. The drug showed no interaction with methotrexate and demonstrated dose-dependent increases in target engagement biomarker HEXIM-11, with maximal effect at 0.5mg to 1.0 mg QD. VYN202 also inhibited multiple inflammatory biomarkers related to Th17 and Th1/myeloid activity.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment